Global Brain Cancer Therapeutics Market Advances at 12.9% CAGR

January 11, 2019

WELLESLEY, Mass, Jan. 11, 2019 – The global brain cancer therapeutics market is thriving, resulting from the rising incidence of brain cancer, early cancer detection, research initiatives, R&D collaborations, an increase in oncology spending and accelerated approvals for drugs used in rare diseases, according to the report “Brain Tumor Therapeutics: Global Markets to 2023.” 

The global market for brain tumor therapeutics was valued at $1.1 billion in 2018 and is expected to reach $2.0 billion by 2023 at a compound annual growth rate (CAGR) of 12.9% during the forecast period, according to BCC Research.

Prominent market players include Roche Holdings AG (RHHBY), Novartis AG (NVS), Merck & Co., Inc. (MRK) and NextSource Biotechnology, LLC.

Research Highlights:

  • Many investigational therapies are being carried out in advanced human clinical trials and many other successful therapeutics are expected to be developed in the near future, which should drive growth in the market.
  • With the vast pipeline of drugs currently in development and the high number of clinical trials conducted worldwide, the market for brain tumor chemotherapeutics is expected to grow at a rapid rate during the forecast period.
  • The Asia-Pacific region is estimated to have the highest growth potential during the forecast period owing to high population growth, unmet need for the development of brain cancer treatments, emerging healthcare awareness and facilities, and additional factors.

“Current therapeutics for brain tumors include chemotherapy, targeted therapy, surgery and radiotherapy,” the report notes. “Many investigational therapies are carried out in advanced human clinical trials. A wide range of immunotherapy drugs, cancer vaccines and successful therapeutics will be developed in the near future. Innovation is expected to result in a surge of market growth in the field.”

Current Trends in the Brain Tumor Therapeutics Market

Current trends in cancer treatment focus on tailoring treatment approaches through molecular biology and genetic understanding of the disease in a particular patient – an approach referred to as personalized medicine. However, in brain tumors, these strategies are currently used as an adjunct to standard treatment protocols and have not yet fully replaced conventional therapy.

Editors/reporters requesting analyst interviews should contact Eric Surber at

Brain Tumor Therapeutics: Global Markets to 2023( PHM208A )
Publish Date: Dec 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.